Pyramax Phase 3 study results published in New England Journal of Medicine
Published: 2012-04-20 06:58:00
Updated: 2012-04-20 06:58:00
Results from a Phase 3 study of pyronaridine-artesunate combination pill Pyramax, approved by EMA for the treatment of falciparum malaria, was published in the New England Journal of Medicine dated April 5, Shinpoong Pharma said yesterday.
The leading medical journal said that Pyramax is as ef...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
